linaclotide sold brand name linzess us mexico constella drug used treat irritable bowel syndrome constipation chronic constipation known black box warning risk serious dehydration children us common adverse effects others include oligopeptide agonist guanylate cyclase remains gi tract taken mouth approved us european union marketed abbvie united states astellas asiacitation needed ironwood pharmaceuticals verification commonly prescribed medication united states million linaclotide indicated treat irritable bowel syndrome constipation chronic constipation known june indication expanded us include treatment functional us label black box warning use linaclotide children less six years old avoid people years old due risk serious people taking linaclotide diarrhea people decreased appetite dehydration low potassium dizziness standing quickly nausea vomiting urgent need defecate fecal incontinence bleeding colon rectum tested pregnant women unknown excreted breast systemic absorption globular tetradecapeptide linaclotide like endogenous guanylin uroguanylin mimics agonist activates cell surface receptor guanylate cyclase medication binds surface intestinal epithelial linaclotide minimally absorbed undetectable systemic circulation therapeutic activation gcc increases cyclic guanosine monophosphate elevated cgmp stimulates secretion chloride bicarbonate water intestinal lumen mainly way cystic fibrosis transmembrane conductance regulator cftr ion channel results increased intestinal fluid accelerated linaclotide hybrid peptide design ecoli heatstable enterotoxin sta endogenous peptide hormones endogenous guanylin synthetic tetradecapeptide amino acid peptide sequence cceyccnpactgcy oneletter abbreviationcitation needed threeletter however actual structure linaclotide fully specified without three disulfide rssr bonds contains shown exaggerated fashion lineangle graphic showing chemical bonds within amino acid stereochemistries see infobox right represented using oneletter abbreviations following additional schematiccitation needed study discovery synthesis reported strategies available synthesize linaclotide successful ones involving trityl protection cysteines trityl protection cysteines except protected tertbutylsulphenyl groups study also reported solutionphase oxidation disulfide formation advisable solidsupported synthesis linaclotide disulfide bridge favored drug discovered microbia inc spun whitehead institute postdocs lab gerald fink commercialize labs knowhow inventions related microbial pathogens company hired mark currie worked searle division monsanto gone currie directed efforts led discovery linaclotide based enterotoxin produced strains escherichia coli cause travelers company started phase trials partnership agreement announced forest laboratories microbia forest would pay million licensing fees towards development linaclotide profits shared two companies us forest obtained exclusive rights market canada microbia changed name ironwood pharmaceuticals licensed rights distribute drug europe almirall licensed asian rights astellas approved united states european union forest acquired eventually became part allergan acquired rights almirall acquired remaining rights rest world excluding north america japan ironwood forest allergan began running directtoconsumer advertising raised sales campaigns raised sales list price linaclotide us pills allergan ironwood increased price linaclotide around httpsenwikipediaorgwikilinaclotide